Home Determination of globotriaosylceramide in plasma and urine by mass spectrometry
Article
Licensed
Unlicensed Requires Authentication

Determination of globotriaosylceramide in plasma and urine by mass spectrometry

  • Ralf Krüger , Kai Bruns , Silke Grünhage , Heidi Rossmann , Jörg Reinke , Michael Beck and Karl J. Lackner
Published/Copyright: December 4, 2009

Abstract

Background: Fabry disease is an X-chromosomally inherited lysosomal storage disorder leading to accumulation of glycosphingolipids, mainly globotriaosylceramide (ceramide-trihexoside, Gb3). Concentrations of Gb3 in plasma and urine have been used to diagnose Fabry disease and to monitor enzyme replacement therapy with recombinant α-galactosidase.

Methods: Gb3 was purified from plasma or urine by combined liquid extraction/protein precipitation and solid-phase extraction, and was detected by flow-injection analysis electrospray mass spectrometry (MS) using multi-reaction-monitoring. Calibration was performed via standard addition using C17-Gb3 as internal standard. The most abundant isoforms were monitored for calculation of total Gb3.

Results: A MS-based assay for quantification of Gb3 in plasma and urine was established and validated. Intra- and inter-assay coefficient of variation (CV) of the method were ≤12%. However, at low concentrations the CV was 16%. The linear range covers roughly two orders of magnitude, down to 0.54 mg/L in plasma and 0.07 mg/L in urine. Careful adjustment of tuning parameters was necessary to obtain identical isoform intensities and quantitative results on different mass spectrometers. Gb3 concentrations in healthy controls were <4 mg/L in EDTA-plasma and <10 μg/mmol creatinine in urine. Significantly increased Gb3 concentrations were found in plasma and urine from male and female patients with Fabry disease.

Conclusions: An improved MS protocol for Gb3 quantification has been developed, validated, and shown to be suitable for diagnosis and monitoring of Fabry patients.

Clin Chem Lab Med 2010;48:189–98.


Corresponding author: Dr. Ralf Krüger, Institute of Clinical Chemistry and Laboratory Medicine, Medical Center of the Johannes Gutenberg University, Langenbeckstr. 1, 55131 Mainz, Germany

Received: 2009-7-10
Accepted: 2009-10-7
Published Online: 2009-12-04
Published in Print: 2010-02-01

©2010 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Review
  2. Elevated serum γ-glutamyltransferase activity is associated with increased risk of mortality, incident type 2 diabetes, cardiovascular events, chronic kidney disease and cancer – a narrative review
  3. Minireview
  4. Artificial intelligence for diagnostic purposes: principles, procedures and limitations
  5. General Clinical Chemistry and Laboratory Medicine
  6. Association between serum alkaline phosphatase and C-reactive protein in the United States National Health and Nutrition Examination Survey 2005–2006
  7. Association between serum uric acid and non-alcoholic fatty liver disease in Korean adults
  8. Plasma osteopontin concentrations in preeclampsia – is there an association with endothelial injury?
  9. Determination of globotriaosylceramide in plasma and urine by mass spectrometry
  10. Effect of inflammation induced by prolonged exercise on circulating erythroid progenitors and markers of erythropoiesis
  11. The Beckman DxI 800 prolactin assay demonstrates superior specificity for monomeric prolactin
  12. Stability of cerebrospinal fluid/serum glucose ratio and cerebrospinal fluid lactate concentrations over 24 h: analysis of repeated measurements
  13. O-β-N-acetyl-D-glucosaminidase in erythrocytes of Italian air force acrobatic pilots
  14. Validation and Outcome Studies
  15. Experimental validation of specificity of the squamous cell carcinoma antigen-immunoglobulin M (SCCA-IgM) assay in patients with cirrhosis
  16. Performance analysis of the ARCHITECT anti-cyclic citrullinated peptide antibody in the diagnosis of rheumatoid arthritis
  17. Reference Values and Biological Variations
  18. Applicability of common reference intervals for serum creatinine concentrations to the Croatian population
  19. Laboratory reference intervals during pregnancy, delivery and the early postpartum period
  20. Determination of serum holotranscobalamin concentrations with the AxSYM active B12 assay: cut-off point evaluation in the clinical laboratory
  21. Definition of reference ranges for the platelet distribution width (PDW): a local need
  22. Cancer Diagnostics
  23. Mean leukocyte telomere length and risk of incident colorectal carcinoma in women: a prospective, nested case-control study
  24. Heat shock protein 27 is over-expressed in tumor tissues and increased in sera of patients with gastric adenocarcinoma
  25. Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels
  26. A novel sensitive immunoassay by nucleic acid barcode dot and its application in the detection of prostate-specific antigen
  27. Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays
  28. Infectious Diseases
  29. Use of flow cytometry (Sysmex® UF-100) to screen for positive urine cultures: in search for the ideal cut-off
  30. Letters to the Editor
  31. Improving laboratory efficiencies through significant time reduction in the preanalytical phase
  32. Comparison of the Vitek 2 system with the CLSI broth microdilution, disk diffusion, and sterol quantitation methods for determining fluconazole susceptibility against Candida spp.
Downloaded on 16.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/CCLM.2010.048/html
Scroll to top button